Cytori Therapeutics (CYTX)

Business description

Cytori sells the Celution device to harvest and concentrate Adipose-Derived Regenerative Cells (ADCR) at the bedside for autologous cell therapy. Celution is CE marked and also sold in Japan.

Share price chart

Share chart

Stock data

Market cap.US$129.8m
Last closeUS$1.20
High / Low (52 weeks)US$2.8 / US$0.4
Stock market listingUS
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual7.1153.1(54.4)
Relative *8.1152.4(59.4)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
Avacta Group AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Cardio3 BioSciences
Carmat Celldex Therapeutics
Cellectis Cerulean
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel Consort Medical
Curis Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Xencor Zafgen
Zealand Pharma Zeltia
Ziopharm Oncology

Company news

Why Cytori Therapeutics (CYTX) Stock Might be a Great Pick

Mon, 30 Mar 2015 11:15:00 GMT

Roth Capital Reiterates Upbeat View of Cytori Therapeutics Inc Following FY14 ...

Fri, 13 Mar 2015 17:30:49 GMT

Why Cytori Therapeutics (CYTX) Stock Might be a Great Pick - Tale of the Tape

Mon, 30 Mar 2015 11:15:00 GMT

Trending Shares In The Bearish Zone: Cytori Therapeutics, Inc. (NASDAQ:CYTX ...

Thu, 19 Mar 2015 07:18:45 GMT

Four Stocks Seeking Failure: Cytori Therapeutics Inc (NASDAQ:CYTX), Frontline ...

Wed, 18 Mar 2015 11:15:00 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2013A 12.2 (32.6) (38.1) (56.2) N/A N/A
2014A 10.1 (34.7) (41.2) (52.5) N/A N/A
2015E N/A N/A N/A N/A N/A N/A
2016E N/A N/A N/A N/A N/A N/A

Last updated on 20/03/2015

Investment summary

Cytori has FDA approval for the pivotal Phase III STAR Trial, enrolling 80 patients with impaired hand function from scleroderma at up to 12 US sites. Enrolment should start in the next few months. This uses ECCS-50: a specific ADRC preparation. The $12m BARDA contract to develop an ADRC thermal burns indication was extended by $2m in December 2014. FY14 revenues were $7.6m with a loss of $38.5m. End 2014 cash was $14.6m with debt of $25.4m. Management indicates an operational burn in 2015 of $25m offset by $6-8m in BARDA contract fees and up to $0.3m in net sales. Our forecasts are under review.

Last updated on 31/03/2015

Industry outlook

A 90-patient US Phase II study in knee osteoarthritis is underway; data are due in H216. Cruciate ligament and knee meniscus indications may be developed. The ATHENA cardiac trial was truncated at 31 patients. A Japanese urinary incontinence study is part-sponsored. EU operations are now based in the UK. In Japan, Cytori may see faster progress on gaining therapeutic claims and reimbursement.

Last updated on 31/03/2015

Key management

Marc Hendrick, CEO
Tiago Girao, CFO

Company address

3020 Callan Road
San Diago
CA 92121
United States
+1.858.458.0900
View website